NEW YORK, February 7, 2017 /PRNewswire/ --
Biotech companies are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Today, Stock-Callers.com reviews the recent performances of these four stocks: Inovio Pharmaceuticals Inc. (NASDAQ: INO), Intra-Cellular Therapies Inc. (NASDAQ: ITCI), PhaseRx Inc. (NASDAQ: PZRX), and Global Blood Therapeutics Inc. (NASDAQ: GBT). These stocks research reports can be downloaded now by simply registering for free at:
On Monday, shares in Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc. recorded a trading volume of 772,741 shares. The stock ended the session 2.83% lower at $6.52. The Company's shares have gained 9.03% in the previous three months. The stock is trading 5.92% below its 50-day moving average. Moreover, shares of Inovio Pharma, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have a Relative Strength Index (RSI) of 45.81.
On December 21st, 2016, Inovio Pharma announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase-I trial. The Company stated that in initial testing, Zika-naïve subjects in both low dose and high dose vaccine groups demonstrated Zika antigen-specific antibody responses after one or two vaccinations. In addition, the vaccine was well tolerated and no significant safety concerns were noted in any of the 40 subjects out to 14 weeks from initiation of dosing. Your complete research report on INO can be retrieved for free at:
New York headquartered Intra-Cellular Therapies Inc.'s stock closed the day 2.76% higher at $14.54 with a total trading volume of 354,118 shares. The Company's shares have surged 33.76% in the previous three months. The stock is trading 2.42% below its 50-day moving average. Additionally, shares of Intra-Cellular Therapies, which discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system, have an RSI of 49.30.
As per a SEC filing dated January 10th, 2017, ITI Limited, a wholly-owned subsidiary of Intra-Cellular Therapies, entered into a supply agreement with Siegfried Evionnaz S.A. on January 04th, 2017. Under the Agreement, Siegfried has agreed to manufacture and supply the active pharmaceutical ingredient that is used in the Company's lead product candidate, ITI-007, in commercial quantities. Each month, ITI Ltd will provide Siegfried with a rolling forecast of ITI Ltd's anticipated requirements for supply of the Product, with the first 12 months of each forecast being binding on ITI Ltd. Under the agreement, ITI Ltd's purchase prices for supply of the product from Siegfried are specified prices based on the volume of product produced. The term of the supply agreement extends for five years. A free report on ITCI is just a click away at:
Shares in Seattle, Washington headquartered PhaseRx Inc. recorded a trading volume of 66,011 shares, and ended yesterday's trading session 6.33% lower at $1.63. The stock has advanced 12.41% in the past month, 18.98% in the previous three months, and 5.16% on an YTD basis. The Company's shares are trading above their 50-day moving average by 4.62%. Furthermore, shares of PhaseRx, which engages in developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children, have an RSI of 54.74. Sign up for your complimentary research report on PZRX at:
Global Blood Therapeutics
South San Francisco, California headquartered Global Blood Therapeutics Inc.'s stock finished Monday's session 0.62% higher at $16.20 with a total trading volume of 172,023 shares. The Company's shares have advanced 6.93% over the previous three months and 12.11% since the start of this year. The stock is trading below its 50-day moving average by 1.03%. Additionally, shares of Global Blood Therapeutics, which engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders, have an RSI of 50.90.
On January 18th, 2017, Global Blood Therapeutics announced enrollment of the first patient in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a pivotal Phase-3 clinical trial of GBT440 in people with sickle cell disease (SCD). The HOPE Study will be conducted at leading SCD sites globally and is expected to enroll up to 400 adults and adolescents with SCD who have had at least one episode of vaso-occlusive crisis (VOC) in the previous year. Register for free on Stock-Callers.com and download the latest research report on GBT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA